Hepatic Impairment
260
16
16
216
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
41 trials with published results (16%)
Research Maturity
216 completed trials (83% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.1%
8 terminated out of 260 trials
96.4%
+9.9% vs benchmark
1%
3 trials in Phase 3/4
19%
41 of 216 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 216 completed trials
Clinical Trials (260)
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Phase 1 Study of Radiprodil in Participants With Hepatic Impairment
An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012)
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
A Study About Fazirsiran in People With and Without Liver Problems
Study of Nalbuphine ER in Participants With Hepatic Impairment
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)
A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)